Megan Thomas spoke with Dan Passeri, CEO of Cue Biopharma, about why the company’s pipeline of cytokine-based drugs are so promising for cancer treatment. MT: Why is this a promising area of oncology research? DP: Cytokines, such as interleukin 2 (IL-2), are potent immunostimulant molecules and well-characterised activators of T cells. As such, they have […]